No abstract

Molecularly imprinted polymers (MIPs) are chemically synthesized materials mimicking the recognition of antibodies towards antigens.

Plasmonic nanomaterials have been widely used for photothermal therapy (PTT) of cancer, but their recognition specificity remains challenging. We prepared monosaccharide-imprinted gold nanorods (AuNRs) for targeted cancer PTT, using sialic acid (SA) as a representative monosaccharide. The SA-imprinted AuNRs exhibited good specificity, enabling the killing of cancer cells without damaging healthy cells.

Due to the unique narrow-band red emission and broadband blue light excitation, as well as milder synthesis conditions, Mn 4+ ion activated fluoride red phosphors show great promise for white light emitting diode (W-LED) applications. However, as the Mn 4+ emission belongs to a spin-forbidden transition ( 2 E g → 4 A 2 ), it is a fundamental challenge to synthesize these phosphors with a high external quantum efficiency (EQE) above 60%. Herein, a highly efficient and thermally stable red fluoride phosphor, Cs 2 SiF 6 :Mn 4+ , with a high internal quantum efficiency (IQE) of 89% and ultrahigh EQE of 71% is demonstrated. Furthermore, nearly 95% of the room-temperature IQE and EQE are maintained at 150 °C. The static and dynamic spectral measurements, as well as density functional theory (DFT) calculations, show that the excellent performance of Cs 2 SiF 6 :Mn 4+ is due to the Mn 4+ ions being evenly distributed in the host lattice Cs 2 SiF 6 . By employing Cs 2 SiF 6 :Mn 4+ as a red light component, stable 10 W high-power warm W-LEDs with a luminous efficiency of ∼110 lm/W could be obtained. These findings indicate that red phosphor Cs 2 SiF 6 :Mn 4+ may be a highly suitable candidate for fabricating high-performance high-power warm white LEDs.

Blocking the HER2 signaling pathway has been an effective strategy in the treatment of HER2-positive breast cancer.I tm ainly relies on the use of monoclonal antibodies and tyrosine-kinase inhibitors.H erein, we present an ew strategy,the nano molecularly imprinted polymer (nanoMIP). The nanoMIPs,imprinted using HER2 N-glycans,could bind almost all HER2 glycans and suppress the dimerization of HER2 with other HER family members,b locking the downstream signaling pathways,t herebyi nhibiting HER2 + breast cancer growth. In vitro experiments demonstrated that the nanoMIPs specifically targeted HER2 + cells and inhibited cell proliferation by 30 %. In vivo experiments indicated that the mean tumor volume of the nanoMIP-treated group was only about half of that of the non-treated groups.T his study provides not only an ew possibility to treat of HER2 + breast cancer but also new evidence to boost further development of nanoMIPs for cancer therapy.